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ysis (PD) patients, which leads to dialysis discontinuation.
Periostin, increased by transforming growth factor b1 (TGF-
b1) stimulation, induces the expression of extracellular matrix
(ECM) genes. Aberrant periostin expression has been
demonstrated to be associated with PD-related peritoneal
ﬁbrosis. Therefore, the effect of periostin inhibition by an ap-
tamer-based inhibitor on peritoneal ﬁbrosis was evaluated.
In vitro, TGF-b1 treatment upregulated periostin, ﬁbronectin,
a-smooth muscle actin (a-SMA), and Snail expression and
reduced E-cadherin expression in human peritoneal mesothe-
lial cells (HPMCs). Periostin small interfering RNA (siRNA)
treatment ameliorated the TGF-b1-induced periostin, ﬁbro-
nectin, a-SMA, and Snail expression and restored E-cadherin
expression in HPMCs. Similarly, the periostin-binding DNA
aptamer (PA) also attenuated ﬁbronectin, a-SMA, and Snail
upregulation and E-cadherin downregulation in TGF-b1-stim-
ulated HPMCs. In mice treated with PD solution for 4 weeks,
the expression of periostin, ﬁbronectin, a-SMA, and Snail
was signiﬁcantly increased in the peritoneum, whereas E-cad-
herin expression was signiﬁcantly decreased. The thickness of
the submesothelial layer and the intensity of Masson’s tri-
chrome staining in the PD group were signiﬁcantly increased
compared to the untreated group. These changes were signiﬁ-
cantly abrogated by the intraperitoneal administration of PA.
These ﬁndings suggest that PA can be a potential therapeutic
strategy for peritoneal ﬁbrosis in PD patients.Received 27 October 2016; accepted 3 May 2017;
http://dx.doi.org/10.1016/j.omtn.2017.05.001.
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Peritoneal dialysis (PD) is a commonly used renal replacement mo-
dality to treat end-stage renal disease patients. However, long-term
PD leads to peritoneal ﬁbrosis in most patients receiving PD.1 The
progression of peritoneal ﬁbrosis invariably causes membrane failure,
leading to volume control failure and loss of dialysis adequacy result-
ing in the discontinuation of PD.2–4 However, detailed molecular
mechanisms underlying peritoneal ﬁbrosis development and progres-
sion have not been fully elucidated. Therefore, the strategies to396 Molecular Therapy: Nucleic Acids Vol. 7 June 2017 ª 2017 The Au
This is an open access article under the CC BY-NC-ND license (httpprevent peritoneal ﬁbrosis and to treat established peritoneal ﬁbrosis
are limited.
The peritoneal membrane is covered by a single layer of peritoneal
mesothelial cells (PMCs), which are supported by a submesothelial
connective tissue area composed of ﬁbroblasts, mast cells, and macro-
phages.5 Recently, PMCs were suggested to play a key role in the
development and progression of peritoneal ﬁbrosis by producing
type I and type II collagen and ﬁbronectin.6 The synthesis of these
extracellular matrix (ECM) proteins by PMCs is accompanied by a
complex mechanism called the epithelial-mesenchymal transition
(EMT).7 EMT of PMCs and their excessive production of ECM pro-
teins are largely attributed to the activation of the transforming
growth factor b1 (TGF-b1) pathway.8 PD ﬂuid is known to increase
the production of TGF-b1 by PMCs,9 and the high glucose level in the
peritoneal dialysate has been shown to be a primary cause of this up-
regulation of TGF-b1 in PMCs.10
Periostin is an ECM protein and is upregulated by the activation of
the TGF-b1 pathway in several cell types.11 It functions as a ligand
of aV/b3 and aV/b5 integrin to activate integrin-related intracellular
signaling pathways, resulting in the increased transcription of ECM
genes, such as collagen and ﬁbronectin.12–15 Recently, periostin levels
in the PD ﬂuid were demonstrated to be upregulated in patients with
encapsulated peritoneal sclerosis, indicating the possibility that peri-
ostin contributes to peritoneal ﬁbrosis in patients undergoing PD.16
Aptamers are single-stranded oligonucleotides that bind to speciﬁc
target molecules. Once bound to a speciﬁc target, some aptamersthor(s).
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www.moleculartherapy.orgare capable of inhibiting its activity.17 Monoclonal antibodies have
been applied in the clinical ﬁeld to suppress the activity of speciﬁc
proteins. However, using antibodies to treat diseases is accompanied
by some critical limitations, such as low bio-stability, the induction of
undesirable immune responses, and high production costs. In
contrast, aptamers are produced chemically and are relatively bio-sta-
ble, resulting in lower production costs and more convenient storage
and distribution compared with antibodies.17,18 They are also less
immunogenic and therefore are associated with a lower risk of devel-
oping hypersensitivity reactions. Due to these advantages, aptamers
have been proposed as promising drug candidates to inhibit speciﬁc
target molecules in various diseases.19–21
Previously, a benzyl-d(U)TP-modiﬁed DNA aptamer, that binds
selectively to periostin, was shown to disrupt the interaction with
its receptor integrins in breast cancer cells.21 In this study, the effects
of this periostin-binding DNA aptamer (PA) on TGF-b1-induced
EMT and ECM accumulation were evaluated using human PMCs
(HPMCs) and a murine model of the PD.
RESULTS
TGF-b1 Upregulates Periostin Expression and Mediates EMT in
HPMCs
First, to verify that periostin is expressed during the EMT process of
HPMCs, the expression of periostin was evaluated in HPMCs treated
with TGF-b1. HPMCs treated with TGF-b1 (2 ng/mL) showed signif-
icantly increased expression of periostin mRNA and protein. This
increase in periostin mRNA expression was accompanied by the up-
regulation of ﬁbronectin, a-smooth muscle actin (a-SMA), and Snail
and downregulation of E-cadherin mRNA expression. The protein
levels of ﬁbronectin, a-SMA, Snail, and E-cadherin showed a similar
expression pattern as the corresponding mRNA levels in HPMCs
(Figure 1). These results indicate that TGF-b1 administration induces
EMT in HPMCs along with a signiﬁcant upregulation of periostin.
Periostin Knockdown Abrogates TGF-b1-Induced EMT in
HPMCs
To evaluate the role of periostin in the EMT process of HPMCs, peri-
ostin expression was knocked down by small interfering RNA
(siRNA) transfection in TGF-b1-stimulated HPMCs. As shown in
Figure 2A, TGF-b1 (2 ng/mL) induced ﬁbroblast-like cell morpho-
logical changes characterized by thin spindle-like cell shapes, in
contrast to the cuboidal shape of unstimulated HPMCs. Interest-
ingly, periostin siRNA (100 nM) administration markedly amelio-
rated the TGF-b1-induced cell morphological changes. This
intriguing result prompted the examination of whether periostin
knockdown normalized the expression of mesenchymal markers
triggered by TGF-b1 in HPMCs. As expected, periostin knockdown
by siRNA administration effectively inhibited periostin expression
induced by TGF-b1 treatment. The expression of ﬁbronectin,
a-SMA, and Snail mRNA also signiﬁcantly decreased in HPMCs
treated with TGF-b1 and periostin siRNA compared to HPMCs
treated with TGF-b1 alone, and the decreased E-cadherin mRNA
level in TGF-b1-stimulated HPMCs was signiﬁcantly restored byperiostin siRNA transfection. Regarding the protein levels, periostin
siRNA signiﬁcantly attenuated the increases in periostin, ﬁbronectin,
a-SMA, and Snail expression and the decrease in E-cadherin expres-
sion induced by TGF-b1 (Figure 2). Together, these results suggest
that periostin upregulation is an essential factor in the EMT process
of TGF-b1-stimulated HPMCs and that periostin inhibition can
mitigate the pathologic EMT of HPMCs.
Confirmation of DNA Aptamer Binding to Periostin in HPMCs
After conﬁrming that periostin played a role in EMT induction in
HPMCs, it was determined whether a PA could affect the EMT
process in HPMCs. First, ﬂuorescence-activated cell sorting (FACS)
analysis was conducted to show that the PA attached speciﬁcally to
periostin in HPMCs. A ﬂuorescein isothiocyanate (FITC)-tagged
PA was used to evaluate the amount of the PA that attached to peri-
ostin expressed in HPMCs. Compared to the negative control, the
FITC-tagged PA-treated cells showed an increase in the FITC-posi-
tive fraction of the total HPMC count (10.6%). The FITC-positive
fraction further increased to 88.2% in TGF-b1- (10 ng/mL) stimu-
lated HPMCs treated with the FITC-tagged PA (200 nM), which
was signiﬁcantly abrogated by periostin siRNA (100 nM) transfection
(24.0%). These ﬁndings suggest that the PA speciﬁcally binds to peri-
ostin expressed by HPMCs (Figure 3).
PA Ameliorates TGF-b1-Induced EMT in HPMCs
To determine whether blocking periostin signaling with the PA
could affect the EMT process, the changes in cell morphology and
the expression of EMT-related molecules were examined after
treatment with the PA in TGF-b1-stimulated HPMCs. The spin-
dle-shaped feature of HPMCs exposed to TGF-b1 (2 ng/mL) was
signiﬁcantly alleviated by the PA treatment (Figure 4), which was
similar to the ﬁndings observed in TGF-b1-stimulated HPMCs
transfected with periostin siRNA (Figure 2). When the cells were
examined for periostin expression, the increases in periostin
mRNA and protein expression following TGF-b1 stimulation were
not signiﬁcantly changed by the PA treatment. In contrast, the upre-
gulated ﬁbronectin, a-SMA, and Snail expression and the downregu-
lated E-cadherin expression in TGF-b1-stimulated HPMCs were
signiﬁcantly attenuated by the PA treatment. These results indicate
that the PA effectively mitigates the TGF-b1-induced EMT process
in HPMCs by inhibiting periostin-related pathway activation rather
than periostin expression.
PA Prevents Peritoneal Fibrosis in PD Mouse Models
To investigate the in vivo effect of the PA on the development of peri-
toneal ﬁbrosis, the PA was administered to a mouse model of the PD.
The peritoneal morphology and EMT-related molecules were exam-
ined in mice treated with the PD solutions for 4 weeks with or without
the intraperitoneal PA administration. Masson’s trichrome staining
and immunohistochemical staining of the peritoneum revealed
signiﬁcantly higher ECM accumulation and periostin expression in
mice treated with the PD solution relative to untreated mice. Aptamer
treatment signiﬁcantly abrogated the ECM accumulation in the PD
mice. Periostin expression was also attenuated by the PA treatmentMolecular Therapy: Nucleic Acids Vol. 7 June 2017 397
Figure 1. Expression of Periostin and EMT-Related Molecules in HPMCs Exposed to TGF-b1
(A) Periostin, fibronectin, E-cadherin, a-SMA, and Snail mRNA levels in HPMCs treated with or without TGF-b1 (2 ng/mL) (n = 12). The TGF-b1 significantly induced
fibronectin, a-SMA, and Snail mRNA expression and significantly reduced E-cadherin mRNA expression in HPMCs. The periostin mRNA expression was also significantly
increased by TGF-b1. (B) A representative western blot analysis of periostin, fibronectin, E-cadherin, a-SMA, Snail, and b-actin protein expression in HPMCs treated with or
without TGF-b1 (2 ng/mL) (a representative of four blots). The protein expression of periostin, fibronectin, a-SMA, and Snail significantly increased and that of E-cadherin
significantly decreased in the TGF-b1-stimulated cells (n = 12). All error bars represent SD of the mean. Un, untreated. *p < 0.01 versus untreated.
Molecular Therapy: Nucleic Acidsin the PD mice. The changes in the expression of EMT-related mol-
ecules in the peritoneum of the PD mice were also signiﬁcantly
ameliorated by the administration of the PA (Figure 5). Furthermore,
ﬁbronectin, a-SMA, and Snail mRNA and protein expression levels
were signiﬁcantly higher and E-cadherin expression was signiﬁcantly
lower in mice treated with the PD solution compared to untreated
mice, and these changes were signiﬁcantly attenuated by the PA treat-
ment (Figure 6). These ﬁndings suggest that the PA can effectively
prevent the PD-induced peritoneal ﬁbrosis.398 Molecular Therapy: Nucleic Acids Vol. 7 June 2017DISCUSSION
In the present study, periostin was found to play a role in TGF-b1-
induced EMT in cultured HPMCs. The inhibition of periostin func-
tion by the PA resulted in the abrogation of TGF-b1-induced EMT.
In addition, the intraperitoneal administration of the PA successfully
inhibited peritoneal ﬁbrosis in an animal model of the PD.
In PD, long-term dialysate exposure results in ﬁbrotic changes in the
peritoneum, decreasing the efﬁciency of solute diffusion and salt
Figure 2. Changes in Cell Morphology and mRNA and Protein Expression of EMT-Related Molecules following Periostin siRNA Transfection
(A) Cell morphology of untreated and TGF-b1- (2 ng/mL) stimulated HPMCswith or without periostin siRNA (100 nM) transfection. The TGF-b1 treatment provoked fibroblast
like cell morphological changes in HPMCs, and periostin siRNA transfection reversed these TGF-b1-induced cell morphological changes (100). (B) mRNA levels in TGF-b1
stimulated HPMCs treated with or without periostin siRNA (n = 12). The periostin siRNA significantly attenuated TGF-b1-induced increases in fibronectin, a-SMA, and Sna
mRNA expression and restored the downregulated E-cadherin mRNA level in HPMCs treated with TGF-b1. The positive control GAPDH siRNA transfection significantly
(legend continued on next page
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Figure 3. Specific Attachment of PA to Periostin Expressed in HPMCs
FACS analysis was performed in HPMCs treated with or without TGF-b1 (10 ng/mL), periostin siRNA (100 nM), or FITC-labeled PA (200 nM). The FITC-positive fraction was
significantly increased in TGF-b1-stimulated HPMCs treated with the FITC-labeled PA, which was significantly abrogated by periostin siRNA transfection. All error bars
represent SD of the mean. Un, untreated; siPeriostin, periostin siRNA; SA, negative control scramble aptamer; PA, periostin-binding DNA aptamer. *p < 0.01 versus un-
treated; #p < 0.01 versus TGF-b1.
Molecular Therapy: Nucleic Acidsremoval from the peritoneal capillary vessels to the peritoneal space, a
condition termed ultraﬁltration failure.22,23 This ultraﬁltration failure
is a major factor that limits the widespread use of the PD as a long-
term renal replacement modality. The results of this study indicate
the possible effectiveness of the intraperitoneal administration of a
PA in the PD patients to prevent ultraﬁltration failure. Moreover,
due to the advantages of aptamers compared to protein- or small-
molecule-based treatment options, such as lower manufacturing costs
and fewer side effects, the current ﬁndings demonstrate that treat-
ment with the PA is a practical and effective strategy to inhibit PD-
induced peritoneal ﬁbrosis and has potential clinical applications.
Continual exposure to dialysate solutions as well as recurrent perito-
nitis episodes cause peritoneal inﬂammation and injury, eventuallydownregulated GAPDH mRNA level. The negative control scramble siRNA transfectio
analysis of protein expression in TGF-b1-stimulated HPMCs with or without periostin s
significantly mitigated the increases in periostin, fibronectin, a-SMA, and Snail protein e
HPMCs. The positive control GAPDH siRNA transfection significantly downregulated G
the expression of protein levels (n = 12). (D) mRNA levels in TGF-b1-stimulated HPMC
significantly attenuated TGF-b1-induced increases in fibronectin, a-SMA, and Snail mR
dependent manner. (E) A representative western blot analysis of protein expression in
representative of four blots). The periostin siRNA transfection significantly mitigated
expression and the decrease in E-cadherin protein expression in a dose-dependent m
ofectamine; siGAPDH, GAPDH siRNA; Scr, negative control scramble siRNA; siPeriost
400 Molecular Therapy: Nucleic Acids Vol. 7 June 2017leading to peritoneal ﬁbrosis.24 PMCs have been implicated as one
of the major cellular elements in the pathogenesis of this peritoneal
ﬁbrosis. In the past, resident peritoneal ﬁbroblasts and inﬁltrating in-
ﬂammatory cells have been considered the key players promoting
peritoneal ﬁbrosis.25 However, recent studies have shown that the
EMT of mesothelial cells is an important process in the induction
of ﬁbrosis and subsequent deterioration of peritoneal function.6,24,26
It has also been demonstrated to be a key process in embryonic devel-
opment, malignant cell metastasis, and the promotion of organ
ﬁbrosis.27 In the case of peritoneal ﬁbrosis, PMCs have been found
to lose their epithelial cytokeratins and gain the expression of mesen-
chymal cellular molecules upon exposure to dialysate.28 In the present
study, TGF-b1 treatment of cultured HPMCs signiﬁcantly downregu-
lated E-cadherin expression and clearly upregulated a-SMA and Snailn did not affect the expression of mRNA levels. (C) A representative western blot
iRNA transfection (a representative of four blots). The periostin siRNA transfection
xpression and the decrease in E-cadherin protein expression in TGF-b1-stimulated
APDH protein level. The negative control scramble siRNA transfection did not affect
s transfected with different doses of periostin siRNA (n = 12). The periostin siRNA
NA expression and restored the downregulated E-cadherin mRNA level in a dose-
TGF-b1-stimulated HPMCs with different doses of periostin siRNA transfection (a
the TGF-b1-induced increases in periostin, fibronectin, a-SMA, and Snail protein
anner (n = 12). All error bars represent SD of the mean. Un, untreated; Lipo, lip-
in, periostin siRNA. *p < 0.01 versus untreated; #p < 0.01 versus TGF-b1.
Figure 4. Changes in Cell Morphology and mRNA and Protein Expression following PA Treatment
(A) Morphologic features of control and TGF-b1- (2 ng/mL) stimulated HPMCs with or without PA treatment (200 nM). The PA inhibited the fibroblast-like cell morphological
changes in HPMCs exposed to TGF-b1 (100). (B) mRNA levels in TGF-b1-stimulated HPMCs treated with or without PA (n = 12). The PA significantly attenuated TGF-b1-
induced fibronectin, a-SMA, and Snail mRNA expression and significantly restored the decrease in E-cadherin mRNA expression in HPMCs stimulated with TGF-b1. The
negative control scramble aptamer treatment did not affect the expression of mRNA levels. (C) A representative western blot analysis of protein expression in HPMCs treated
with or without PA (a representative of four blots). The PA significantly mitigated the increases in fibronectin, a-SMA, and Snail protein expression and the decrease in
E-cadherin protein expression in TGF-b1-stimulated HPMCs. The negative control scramble aptamer treatment did not affect the expression of protein levels (n = 12). All error
bars represent SD of the mean. Un, untreated; SA, negative control scramble aptamer; PA, periostin-binding DNA aptamer. *p < 0.01 versus untreated; #p < 0.01 versus
TGF-b1.
www.moleculartherapy.orgexpression, which was accompanied by a signiﬁcant increase in ﬁbro-
nectin expression. A similar ﬁnding was also found in the peritoneal
tissue of the PD mice. These ﬁndings suggest that EMT is involved in
the course of the PD-induced peritoneal ﬁbrosis and that PMCs play a
signiﬁcant role in this process, which is in accordance with the results
of previous studies.29,30
TGF-b1 is a well-known proﬁbrotic cytokine that plays key patholog-
ical roles, including EMT promotion, in peritoneal ﬁbrosis in patients
undergoing the PD.31 TGF-b1 activates Smad2 and Smad3, which
consequently induces a molecular transition that results in the down-
regulation of the intracellular adhesion molecule E-cadherin and
upregulation of mesenchymal-associated molecules, such as Snail,
a-SMA, and ﬁbronectin. Clinical studies have shown that the levels
of TGF-b1 detected in the PD ﬂuid correlated with the risk of tech-
nical failure in the PD patients.32,33 Furthermore, overexpression of
TGF-b1 by the transfection of adenovirus vectors into the peritonealcavity led to peritoneal ﬁbrosis, angiogenesis, and ultraﬁltration fail-
ure in an animal model of the PD.34 In addition, stimulation of PMCs
in vitro with dialysate-containing culture media resulted in an in-
crease in TGF-b1mRNA and protein expression. Based on these ﬁnd-
ings, TGF-b1 has been considered a key inducer of ﬁbrotic changes in
the peritoneum of patients undergoing the PD, and, therefore, to
simulate the PD environment associated with EMT and ﬁbrosis,
cultured HPMCs were treated with TGF-b1 for the in vitro experi-
ments in this study.
Previously, strategies to inhibit TGF-b1 were evaluated to prevent or-
gan ﬁbrosis in various disease conditions.35 The administration of
TGF-b1 antibodies has been considered as an option for TGF-b1 in-
hibition and has shown promising anti-ﬁbrotic results in some animal
models.36–38 Moreover, substances having an inhibitory effect on
TGF-b1, such as decorin and pirfenidone [5-methyl-1-phenyl-
2(1H)-pyridone], have been tested for their efﬁcacies in variousMolecular Therapy: Nucleic Acids Vol. 7 June 2017 401
Figure 5. Masson’s Trichrome Staining and Immunohistochemical Staining of Periostin, Fibronectin, E-cadherin, a-SMA, and Snail in the Peritoneum of
Untreated, Untreated + PA, PD, and PD + PA Mice
Masson’s trichrome staining and immunohistochemical staining of the peritoneum revealed significantly higher ECM accumulation and periostin expression in mice
treated with PD solution relative to control mice, and PA treatment significantly abrogated ECM accumulation and periostin expression in PD mice. The changes in the
expression of EMT-related molecules in the peritoneum of the PDmice were also significantly ameliorated by the administration of the PA (200). For each group, 12 sections
were evaluated. All error bars represent SD of the mean. Un, untreated; PD, peritoneal dialysis; PA, periostin-binding DNA aptamer. *p < 0.01 versus untreated; #p < 0.01
versus PD.
Molecular Therapy: Nucleic Acidsdiseases, such as systemic sclerosis and glomerulosclerosis.39,40
Regarding peritoneal ﬁbrosis, in vitro studies on PMCs transfected
with TGF-b1 small hairpin RNA (shRNA)-expressing vectors
demonstrated the amelioration of ECM protein synthesis in these
cells.41 However, in addition to promoting pathological ﬁbrotic
changes in disease states, TGF-b1 is also involved in various physio-
logical functions, such as wound healing and immune reactions.42
Furthermore, because TGF-b1 is located upstream of the TGF-b1-
induced ﬁbrosis signaling cascade, inhibition of TGF-b1 blocks
numerous downstream cell signaling pathways critical for cell sur-402 Molecular Therapy: Nucleic Acids Vol. 7 June 2017vival.31 For these reasons, the clinical applications of anti-TGF-b1
therapies have been limited. Therefore, recent investigations have
focused on molecular targets farther downstream of the cell-signaling
cascade to induce anti-ﬁbrotic effects. It should be noted that the
inhibition of periostin, a terminally located protein in the TGF-b1-
induced ﬁbrosis pathway, successfully attenuated the PD-related
ﬁbrosis process in the peritoneum.
Treatment with the PA resulted in signiﬁcant abrogation of EMT
and ﬁbrosis. Previous studies have found that periostin acts as a
Figure 6. Expression of Periostin and EMT-Related Molecules in the Peritoneum of Untreated, Untreated + PA, PD, and PD + PA Mice
(A) Fibronectin, a-SMA, and Snail mRNA expression was significantly higher and E-cadherin expression was significantly lower in mice treated with PD solution compared to
control mice, and these changes were significantly attenuated by PA treatment (n = 12). (B) A representative western blot analysis of periostin, fibronectin, E-cadherin,
a-SMA, Snail, and b-actin protein expression in the peritoneum (a representative of four blots). The protein expression levels of EMT-related molecules showed a similar
pattern as the corresponding mRNA expression levels (n = 12). All error bars represent SD of the mean. Un, untreated; PD, peritoneal dialysis; PA, periostin-binding DNA
aptamer. *p < 0.01 versus untreated; #p < 0.01 versus PD.
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integrin aV/b3 and aV/b5.43 The activation of integrin is known
to involve key cell signaling pathways that contribute to EMT
and ﬁbrosis, such as Akt and p38.44 The periostin-speciﬁc binding
property of the PA has been previously shown to inhibit the
periostin-integrin interaction, thereby suppressing the integrin
signaling pathways.21 This is supported by the results for the peri-
ostin protein levels in this study, which were not changed following
the PA treatment despite its anti-ﬁbrotic effects. Further investiga-
tions on the cellular pathways that are affected by the PA are
needed to conﬁrm this conclusion. In addition, because periostin
expression itself is also known to be regulated by integrin activa-
tion,43 a higher dose of the PA could ultimately downregulate
the expression of periostin. The possibility of periostin level atten-
uation with a higher PA dose treatment could explain the discrep-
ancy found between in vivo and in vitro experiments in this study.
Treatment with the PA signiﬁcantly attenuated the immunohisto-
chemical staining of periostin in the peritoneum of the PD mice,
while a clear amelioration of periostin level was not found in cell
studies. The PA treatment could have had different dose effects be-
tween the experiments.
In conclusion, the results of this study suggest that periostin acts as a
key mediator of peritoneal ﬁbrosis in the PD patients, and treatmentwith the PA can be considered an effective treatment modality for
peritoneal ﬁbrosis in these patients.
MATERIALS AND METHODS
Primary Culture of HPMCs
Primary HPMCs were isolated in accordance with the process re-
ported by Stylianou et al.45 using human omenta specimens from pa-
tients who had undergone abdominal surgery and agreed to provide
consent. The specimens were washed three times using sterile PBS
and incubated in a solution containing 0.05% trypsin and 0.02%
EDTA for 20 min at 37C, with continuous shaking. After an incuba-
tion period, free HPMC-containing suspension was centrifuged at
100 g for 10 min at 4C. The supernatant was removed, and the pellet
was washed once. Subsequently, the pellet was re-suspended into
M199 media supplemented with 10% fetal bovine serum (FBS),
100 U/mL penicillin, 100 mg/mL streptomycin, and 26 mMNaHCO3
and seeded on cell culture dishes. The cells were cultured in the same
media at 37C in humidiﬁed 5% CO2 in air. The media were
exchanged 24 hr after seeding and then every 3 days.
Treatment of HPMCs
Subconﬂuent HPMCs were FBS restricted for 24 hr. Next, the media
were exchanged to FBS-free M199 media for the control group and
media with TGF-b1 (2 ng/mL) (R&D Systems) for the interventionMolecular Therapy: Nucleic Acids Vol. 7 June 2017 403
Table 1. Periostin-Binding DNA Aptamer Sequence
Sequence
Cy3-labled PA Cy3-ACGAGYYGYCGCAYGYGCGGYYCAGYCYGGYCCYYCAGCACCGYACAACAA
FITC-labeled PA FITC-ACGAGYYGYCGCAYGYGCGGYYCAGYCYGGYCCYYCAGCACCGYACAACAA
PEG-conjugated PA PEG-ACGAGYYGYCGCAYGYGCGGYYCAGYCYGGYCCYYCAGCACCGYACAACAA-idT
Y, benzyl-d(U)TP; idT, inverted dT.
Molecular Therapy: Nucleic Acidsgroup. HPMCs were harvested for RNA and protein analyses 72 hr
after media change. For periostin knockdown experiments, periostin
siRNA and negative control scramble siRNA was purchased from
Dharmacon. Positive control GAPDH siRNA was purchased from
Bioneer. Periostin siRNA was transfected with Lipofectamine 2000
(Invitrogen) according to the manufacturer’s protocol. Brieﬂy, 6 mL
of Lipofectamine 2000 was diluted in 1 mL of Opti-MEM I Reduced
Serum Medium (Invitrogen), incubated for 15 min at room temper-
ature (RT), and mixed with periostin siRNA. After a 15 min incuba-
tion at RT, the mixture was added to each well of HPMCs, which were
plated at a density of 5  105 cells/well into 6-well plates the day
before, and the medium was changed after 24 hr. The doses of
TGF-b1 and periostin siRNA for this study were determined based
on preliminary experimental results.
PA
To select periostin-speciﬁc aptamers, a modiﬁed DNA SELEX pro-
cedure was used.21,46 The selected PA and negative control scramble
aptamer were constructed by Aptamer Sciences Inc. as previously re-
ported.21 The sequence of the aptamer used is shown in Table 1. This
aptamer was prepared in three forms: Cy3-labeled aptamer, FITC-
labeled aptamer, and polyethylene glycol (PEG)-conjugated aptamer.
Cy3-labeled PA and FITC-labeled PA were prepared by labeling Cy3
and FITC to the 50 end of the aptamer, respectively. Cy3-labled PA
was used for in vitro studies. FITC-labeled PA was used to evaluate
the periostin-speciﬁc aptamer attachment in the FACS analysis
studies. PEG-conjugated PA was prepared by conjugating 40 kDa
PEG to the 50 end. In addition, the PEG-conjugated PA contained
an inverted deoxythymidine (dT) to the 30 end to increase in vivo bio-
logical stability. The PEG-conjugated PA was applied for animal
studies.
FACS Analysis of HPMCs
HPMCs were centrifuged at 500 g for 5 min and washed twice in an
isotonic, calcium, and magnesium free-PBS buffer to remove resid-
ual growth factors in the medium. A ﬁnal concentration of 1 
107 cells/mL was re-suspended and incubated with 200 nmol/L
FITC-labeled PA containing binding buffer (PBS including 5 mM
MgCl2). Samples of 100 mL were used per assay (1  106 cells)
into each 1.5 mL tube for staining. Flow cytometric analysis of sur-
face staining intensity was performed using an FACSVERSE System
(BD Biosciences) and signals were obtained from a blue laser.
Analysis of the results was conducted using FACSuite software
(BD Biosciences).404 Molecular Therapy: Nucleic Acids Vol. 7 June 2017Animal Experiments
The protocols for animal experiments were approved by the Commit-
tee for the Care and Use of Laboratory Animals at Yonsei University
College of Medicine, Seoul, Korea. All of the animal experiments were
conducted in accordance with the Principles of Laboratory Animal
Care (NIH Publication no. 85-23, revised 1985).
48 male C57BL/6 mice weighing 20–25 g were used. To establish the
PD model, PD catheter and ports (cat # MMP-4S-061108A; Access
Technologies and Solomon Scientiﬁc) were inserted, and the wounds
were observed for 1 week. At 1 week after catheter insertion, the un-
treated group received 2 mL of saline instillation once a day. The PD
group was infused intraperitoneally with 2 mL of peritoneal dialysate
daily (physioneal PD solution with 4.25% dextrose, pH 7.4; Baxter In-
ternational) for 4 weeks. In the untreated + PA group, the PA was
delivered at 500 mg/kg/d mixed with saline. In the PD +PA group,
the PA was delivered at 500 mg/kg/d mixed with the PD ﬂuid. The
mixtures were given through the PD catheter daily in a ﬁnal volume
of 2 mL. The amount of the PA delivered did not include the conju-
gated PEG weight. Preliminary investigations evaluating the amount
of the PA detected in the peritoneum, evaluated by real-time qPCR
were used to select the dosage of the PA delivered (Figure S1). The
primers used to detect the PA are provided in Table 2. After 4 weeks
of treatment, all of the mice were sacriﬁced, and the parietal perito-
neum was collected from each animal.
Real-Time qPCR
The RNA extraction methods fromHPMCs and the peritoneum were
described in a previous study.47 For animal samples, a total of 0.1 g
peritoneum tissue for each animal was used to extract RNA. A Boeh-
ringer Mannheim cDNA Synthesis Kit (Boehringer Mannheim) was
used to obtain ﬁrst-strand cDNA. Using the ABI PRISM 7700
Sequence Detection System (Applied Biosystems), a total volume of
20 mL mixture in each well was used containing 10 mL of SYBR Green
PCR Master Mix (Applied Biosystems), 5 mL of cDNA, and 5 pmol
sense and antisense primers. The primer sequences used in this study
were described in Table 2. The RNAs used for ampliﬁcation were
25 ng per reaction tube. The primer concentrations were determined
by preliminary experiments that analyzed the optimal concentrations
of each primer. The PCR conditions were as follows: 35 cycles of
denaturation for 30 min at 94.5C, annealing for 30 s at 60C, and
extension for 1 min at 72C. Initial heating for 9 min at 95C and ﬁnal
extension for 7 min at 72C were performed for all PCR reactions.
Each sample was run in triplicate in separate tubes and a control
Table 2. Primer Sequences Used for Real-Time qPCR
Sequence (50–30)
Periostin (mouse and human)
sense GGCACCAAAAAGAAATACT
antisense GGAAGGTAAGAGTATAT
Fibronectin (mouse)
sense TGACAACTGCCGTAGACCTGG
antisense TACTGGTTGTAGGTGTGGCCG
Fibronectin (human)
sense AACCTACGGATGACTCGTGC
antisense TGAATCACATCTGAAATGACCAC
E-cadherin (mouse)
sense TTTCTACAGCATCACCGGC
antisense CACTTTCAGCCAGCCTGTC
E-cadherin (human)
sense CACAGACGCGGACGATGAT
antisense AGGATCTTGGCTGAGGATGGT
a-SMA (mouse)
sense CTGACAGAGGCACCACTGAA
antisense CATCTCCAGAGTCCAGCACA
a-SMA (human)
sense GCCTTGGTGTGTGACAATGG
antisense AAAACAGCCCTGGGAGCAT
PA detection
sense ACGAGTTGTCGCATGTGCGGT
antisense TGTTGTACGGTGCTGAAGGACCA
www.moleculartherapy.orgwithout cDNA was also run in parallel with each assay. After real-
time PCR, the temperature was increased from 60C to 95C at a
rate of 2C/min to construct a melting curve. The cDNA content of
each specimen was determined using a comparative CT method
with 2DDCT. The results were given as the relative expression normal-
ized to the expression of 18S rRNA and expressed in arbitrary units.
Western Blot Analysis
Western blotting was performed as described previously.47 For ani-
mal samples, a total of 0.2 g peritoneum tissue for each animal was
used to extract protein. Blots were incubated overnight at 4C with
polyclonal antibodies to periostin (Abcam), E-cadherin (BD Biosci-
ence), a-SMA (Abcam), ﬁbronectin (Dako), Snail (Abcam), GAPDH
(Abcam), or b-actin (Sigma Chemical). The membranes were washed
three times for 10 min in 1 PBS with 0.1% Tween-20 and incubated
in buffer A containing a 1:1,000 dilution of horseradish peroxidase-
linked goat anti-rabbit or anti-mouse IgG (Santa Cruz Biotech-
nology). TINA image software (Raytest) was used to measure the
band densities, and the changes in the optical densities of bands
from the treated groups relative to untreated cells or tissues were
used for analysis.
Immunohistochemical Staining and Masson’s Trichrome
Staining
To ﬁx the peritoneum samples, 10% neutral-buffered formalin was
used. Parafﬁn-embedded tissues were processed in 5 mm-thick sec-
tions for immunohistochemical staining. Tissue sections were de-
parafﬁnized, rehydrated in ethyl alcohol, and washed in tap water.
Antigen retrieval was performed in 10 mM sodium citrate buffer for
20 min using a Black & Decker vegetable steamer. Slides were
blocked with 10% donkey serum for 30 min at RT and then washedusing PBS. Primary antibodies for ﬁbronectin, E-cadherin, a-SMA,
and Snail were diluted to the proper concentrations with 2% casein
in BSA, added to the slides, and then incubated overnight at 4C.
After washing, the slides were treated with a secondary antibody
for 1 hr at RT. Diaminobenzidine was added for 2 min, and hema-
toxylin was used to counterstain the slides. For Masson’s trichrome
staining, parafﬁn-embedded tissues processed in 5 mm-thick sec-
tions were deparafﬁnized, rehydrated in ethyl alcohol, washed in
tap water, and re-ﬁxed in Bouin’s solution for 1 hr at 56C. After
rinsing in running tap water for 10 min and staining with Weigert’s
iron hematoxylin working solution for 10 min, the slides were
stained with Biebrich scarlet-acid fuchsin solution for 15 min and
washed in tap water. The sections were differentiated in phospho-
molybdic-phosphotungstic acid solution for 15 min, transferred
to aniline blue solution, and stained for 10 min. After rinsing brieﬂy
in tap water, the slides were reacted with 1% acetic acid solution for
5 min. A semiquantitative score for staining intensity was assessed
by examining at least ﬁve ﬁelds in each section under 400 magni-
ﬁcation and with digital image analysis (MetaMorph version 4.6r5,
Universal Imaging).
Statistical Analysis
Statistical analyses were conducted using SPSS for Windows version
21 (IBM). Data are expressed as the mean ± SD. One-way ANOVA
with post hoc testing using Bonferroni’s correction was used for mul-
tiple comparisons. A p value less than 0.05 was considered statistically
signiﬁcant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one ﬁgure and can be found with
this article online at http://dx.doi.org/10.1016/j.omtn.2017.05.001.Molecular Therapy: Nucleic Acids Vol. 7 June 2017 405
Molecular Therapy: Nucleic AcidsAUTHOR CONTRIBUTIONS
B.Y.N., J.T.P., J.P.L., and S.-W.K. conceived the project. B.Y.N.,
Y.E.K., S.K., J.P., J.E.U., and M.W. performed the experiments.
J.H.J. and Y.K. constructed the DNA aptamers. B.Y.N., J.T.P.,
S.H.H., T.-H.Y., and S.-W.K. interpreted data. J.T.P., Y.E.K., and
S.-W.K. wrote the manuscript. J.T.P. and S.-W.K. provided ﬁnal
approval for publication.
CONFLICTS OF INTEREST
All authors declare no competing interests.
ACKNOWLEDGMENTS
This work was supported by a faculty research grant from Yon-
sei University College of Medicine (6-2016-0079) and a National
Research Foundation of Korea (NRF) grant funded by the
Korean government (MSIP) (NRF-2014R1A1A1002198 and
NRF-2015R1A2A2A01002308).
REFERENCES
1. Ayuzawa, N., Ishibashi, Y., Takazawa, Y., Kume, H., and Fujita, T. (2012). Peritoneal
morphology after long-term peritoneal dialysis with biocompatible ﬂuid: recent clin-
ical practice in Japan. Perit. Dial. Int. 32, 159–167.
2. Bargman, J.M. (2012). Advances in peritoneal dialysis: a review. Semin. Dial. 25,
545–549.
3. Devuyst, O., Margetts, P.J., and Topley, N. (2010). The pathophysiology of the peri-
toneal membrane. J. Am. Soc. Nephrol. 21, 1077–1085.
4. Kawaguchi, Y., Kawanishi, H., Mujais, S., Topley, N., and Oreopoulos, D.G.;
International Society for Peritoneal Dialysis Ad Hoc Committee on Ultraﬁltration
Management in Peritoneal Dialysis (2000). Encapsulating peritoneal sclerosis: deﬁni-
tion, etiology, diagnosis, and treatment. Perit. Dial. Int. 20 (Suppl 4 ), S43–S55.
5. Brulez, H.F., and Verbrugh, H.A. (1995). First-line defense mechanisms in the
peritoneal cavity during peritoneal dialysis. Perit. Dial. Int. 15, S24–S33, discussion
S33–S34.
6. Yáñez-Mó, M., Lara-Pezzi, E., Selgas, R., Ramírez-Huesca, M., Domínguez-Jiménez,
C., Jiménez-Heffernan, J.A., Aguilera, A., Sánchez-Tomero, J.A., Bajo, M.A., Alvarez,
V., et al. (2003). Peritoneal dialysis and epithelial-to-mesenchymal transition of
mesothelial cells. N. Engl. J. Med. 348, 403–413.
7. Yang, A.H., Chen, J.Y., and Lin, J.K. (2003). Myoﬁbroblastic conversion of mesothe-
lial cells. Kidney Int. 63, 1530–1539.
8. Margetts, P.J., Bonniaud, P., Liu, L., Hoff, C.M., Holmes, C.J., West-Mays, J.A., and
Kelly, M.M. (2005). Transient overexpression of TGF-beta1 induces epithelial mesen-
chymal transition in the rodent peritoneum. J. Am. Soc. Nephrol. 16, 425–436.
9. Oh, K.H., and Margetts, P.J. (2005). Cytokines and growth factors involved in peri-
toneal ﬁbrosis of peritoneal dialysis patients. Int. J. Artif. Organs 28, 129–134.
10. Yao, Q., Pawlaczyk, K., Ayala, E.R., Styszynski, A., Breborowicz, A., Heimburger, O.,
Qian, J.Q., Stenvinkel, P., Lindholm, B., and Axelsson, J. (2008). The role of the TGF/
Smad signaling pathway in peritoneal ﬁbrosis induced by peritoneal dialysis solu-
tions. Nephron Exp. Nephrol. 109, e71–e78.
11. Horiuchi, K., Amizuka, N., Takeshita, S., Takamatsu, H., Katsuura, M., Ozawa, H.,
Toyama, Y., Bonewald, L.F., and Kudo, A. (1999). Identiﬁcation and characterization
of a novel protein, periostin, with restricted expression to periosteum and periodontal
ligament and increased expression by transforming growth factor beta. J. BoneMiner.
Res. 14, 1239–1249.
12. Merle, B., and Garnero, P. (2012). The multiple facets of periostin in bone meta-
bolism. Osteoporos. Int. 23, 1199–1212.
13. Norris, R.A., Damon, B., Mironov, V., Kasyanov, V., Ramamurthi, A., Moreno-
Rodriguez, R., Trusk, T., Potts, J.D., Goodwin, R.L., Davis, J., et al. (2007).
Periostin regulates collagen ﬁbrillogenesis and the biomechanical properties of con-
nective tissues. J. Cell. Biochem. 101, 695–711.406 Molecular Therapy: Nucleic Acids Vol. 7 June 201714. Ontsuka, K., Kotobuki, Y., Shiraishi, H., Serada, S., Ohta, S., Tanemura, A., Yang, L.,
Fujimoto, M., Arima, K., Suzuki, S., et al. (2012). Periostin, a matricellular protein,
accelerates cutaneous wound repair by activating dermal ﬁbroblasts. Exp.
Dermatol. 21, 331–336.
15. Rios, H., Koushik, S.V., Wang, H., Wang, J., Zhou, H.M., Lindsley, A., Rogers, R.,
Chen, Z., Maeda, M., Kruzynska-Frejtag, A., et al. (2005). Periostin null mice exhibit
dwarﬁsm, incisor enamel defects, and an early-onset periodontal disease-like pheno-
type. Mol. Cell. Biol. 25, 11131–11144.
16. Braun, N., Sen, K., Alscher, M.D., Fritz, P., Kimmel, M., Morelle, J., Gofﬁn, E., Jörres,
A., Wüthrich, R.P., Cohen, C.D., and Segerer, S. (2013). Periostin: a matricellular pro-
tein involved in peritoneal injury during peritoneal dialysis. Perit. Dial. Int. 33,
515–528.
17. Song, K.M., Lee, S., and Ban, C. (2012). Aptamers and their biological applications.
Sensors (Basel) 12, 612–631.
18. Keefe, A.D., Pai, S., and Ellington, A. (2010). Aptamers as therapeutics. Nat. Rev.
Drug Discov. 9, 537–550.
19. Apte, R.S. (2008). Pegaptanib sodium for the treatment of age-related macular degen-
eration. Expert Opin. Pharmacother. 9, 499–508.
20. Held, D.M., Kissel, J.D., Patterson, J.T., Nickens, D.G., and Burke, D.H. (2006). HIV-1
inactivation by nucleic acid aptamers. Front. Biosci. 11, 89–112.
21. Lee, Y.J., Kim, I.S., Park, S.A., Kim, Y., Lee, J.E., Noh, D.Y., Kim, K.T., Ryu, S.H., and
Suh, P.G. (2013). Periostin-binding DNA aptamer inhibits breast cancer growth and
metastasis. Mol. Ther. 21, 1004–1013.
22. Margetts, P.J., and Churchill, D.N. (2002). Acquired ultraﬁltration dysfunction in
peritoneal dialysis patients. J. Am. Soc. Nephrol. 13, 2787–2794.
23. Williams, J.D., Craig, K.J., Topley, N., Von Ruhland, C., Fallon, M., Newman, G.R.,
Mackenzie, R.K., and Williams, G.T.; Peritoneal Biopsy Study Group (2002).
Morphologic changes in the peritoneal membrane of patients with renal disease.
J. Am. Soc. Nephrol. 13, 470–479.
24. Lai, K.N., Tang, S.C., and Leung, J.C. (2007). Mediators of inﬂammation and ﬁbrosis.
Perit. Dial. Int. 27 (Suppl 2 ), S65–S71.
25. Jörres, A. (1999). Effect of peritoneal dialysis on peritoneal cell biology: peritoneal ﬁ-
broblasts. Perit. Dial. Int. 19 (Suppl 2 ), S348–S352.
26. Liu, Y., Dong, Z., Liu, H., Zhu, J., Liu, F., and Chen, G. (2015). Transition of meso-
thelial cell to ﬁbroblast in peritoneal dialysis: EMT, stem cell or bystander? Perit.
Dial. Int. 35, 14–25.
27. Grande, M.T., and López-Novoa, J.M. (2009). Fibroblast activation andmyoﬁbroblast
generation in obstructive nephropathy. Nat. Rev. Nephrol. 5, 319–328.
28. López-Cabrera, M. (2014). Mesenchymal conversion of mesothelial cells is a key
event in the pathophysiology of the peritoneum during peritoneal dialysis. Adv.
Med. 2014, 473134.
29. Lee, H.B., and Ha, H. (2007). Mechanisms of epithelial-mesenchymal transition of
peritoneal mesothelial cells during peritoneal dialysis. J. Korean Med. Sci. 22,
943–945.
30. Selgas, R., Bajo, A., Jiménez-Heffernan, J.A., Sánchez-Tomero, J.A., Del Peso, G.,
Aguilera, A., and López-Cabrera, M. (2006). Epithelial-to-mesenchymal transition
of the mesothelial cell–its role in the response of the peritoneum to dialysis.
Nephrol. Dial. Transplant. 21 (Suppl 2 ), ii2–ii7.
31. Böttinger, E.P., and Bitzer, M. (2002). TGF-beta signaling in renal disease. J. Am. Soc.
Nephrol. 13, 2600–2610.
32. Lin, C.Y., Chen, W.P., Fu, L.W., Yang, L.Y., and Huang, T.P. (1997). Persistent trans-
forming growth factor beta 1 expression may predict peritoneal ﬁbrosis in CAPD pa-
tients with frequent peritonitis occurrence. Adv. Perit. Dial. 13, 64–71.
33. Gangji, A.S., Brimble, K.S., and Margetts, P.J. (2009). Association between markers of
inﬂammation, ﬁbrosis and hypervolemia in peritoneal dialysis patients. Blood Purif.
28, 354–358.
34. Margetts, P.J., Kolb, M., Galt, T., Hoff, C.M., Shockley, T.R., and Gauldie, J. (2001).
Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on
membrane function. J. Am. Soc. Nephrol. 12, 2029–2039.
35. Akhurst, R.J., and Hata, A. (2012). Targeting the TGFb signalling pathway in disease.
Nat. Rev. Drug Discov. 11, 790–811.
www.moleculartherapy.org36. Miyajima, A., Chen, J., Lawrence, C., Ledbetter, S., Soslow, R.A., Stern, J., Jha, S.,
Pigato, J., Lemer, M.L., Poppas, D.P., et al. (2000). Antibody to transforming growth
factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney
Int. 58, 2301–2313.
37. Sharma, K., Jin, Y., Guo, J., and Ziyadeh, F.N. (1996). Neutralization of TGF-beta by
anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracel-
lular matrix gene expression in STZ-induced diabetic mice. Diabetes 45, 522–530.
38. Ziyadeh, F.N., Hoffman, B.B., Han, D.C., Iglesias-De La Cruz, M.C., Hong, S.W.,
Isono, M., Chen, S., McGowan, T.A., and Sharma, K. (2000). Long-term prevention
of renal insufﬁciency, excess matrix gene expression, and glomerular mesangial ma-
trix expansion by treatment with monoclonal antitransforming growth factor-beta
antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. USA 97, 8015–8020.
39. Denton, C.P., Merkel, P.A., Furst, D.E., Khanna, D., Emery, P., Hsu, V.M., Silliman,
N., Streisand, J., Powell, J., Akesson, A., et al.; Cat-192 Study Group; Scleroderma
Clinical Trials Consortium (2007). Recombinant human anti-transforming growth
factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, pla-
cebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 56, 323–333.
40. Cho, M.E., Smith, D.C., Branton, M.H., Penzak, S.R., and Kopp, J.B. (2007).
Pirfenidone slows renal function decline in patients with focal segmental glomerulo-
sclerosis. Clin. J. Am. Soc. Nephrol. 2, 906–913.
41. Liu, F., Liu, H., Peng, Y., Yuan, F., Liu, Y., and Duan, S. (2005). Inhibition of trans-
forming growth factor beta (TGFbeta1) expression and extracellular matrix secre-tion in human peritoneal mesothelial cells by pcDU6 vector-mediated TGFbeta1
shRNA and by pcDNA3.1(-)-mediated antisense TGFbeta1 RNA. Adv. Perit.
Dial. 21, 41–52.
42. Wrzesinski, S.H., Wan, Y.Y., and Flavell, R.A. (2007). Transforming growth factor-
beta and the immune response: implications for anticancer therapy. Clin. Cancer
Res. 13, 5262–5270.
43. Morra, L., and Moch, H. (2011). Periostin expression and epithelial-mesenchymal
transition in cancer: a review and an update. Virchows Arch. 459, 465–475.
44. Mael-Ainin, M., Abed, A., Conway, S.J., Dussaule, J.C., and Chatziantoniou, C.
(2014). Inhibition of periostin expression protects against the development of renal
inﬂammation and ﬁbrosis. J. Am. Soc. Nephrol. 25, 1724–1736.
45. Stylianou, E., Jenner, L.A., Davies, M., Coles, G.A., and Williams, J.D. (1990).
Isolation, culture and characterization of human peritoneal mesothelial cells.
Kidney Int. 37, 1563–1570.
46. Davies, D.R., Gelinas, A.D., Zhang, C., Rohloff, J.C., Carter, J.D., O’Connell, D.,
Waugh, S.M., Wolk, S.K., Mayﬁeld, W.S., Burgin, A.B., et al. (2012). Unique motifs
and hydrophobic interactions shape the binding of modiﬁed DNA ligands to protein
targets. Proc. Natl. Acad. Sci. USA 109, 19971–19976.
47. Kang, S.W., Adler, S.G., Lapage, J., and Natarajan, R. (2001). p38 MAPK and MAPK
kinase 3/6 mRNA and activities are increased in early diabetic glomeruli. Kidney Int.
60, 543–552.Molecular Therapy: Nucleic Acids Vol. 7 June 2017 407
